The role of implantable cardioverter defibrillators in high-risk CABG patients identified early post-cardiac surgery

Europace

Volumn 13, Issue 1, 2011, Pages 70-76

  Nageh, Maged F ^a   Kim, John J ^a   Chung, Joanie ^a   Yao, Janis F ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Bypass surgery; Implantable defibrillators; Risk assessment

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CORONARY ARTERY BYPASS GRAFT; DEFIBRILLATOR; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS;

AGED; ARRHYTHMIAS, CARDIAC; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 78650432027     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq351     Document Type: Article

References (28)

1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (MADIT-2). N Engl J Med 2002;346:877-83.
2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (SCD-HeFT). N Engl J Med 2005;352:225-37.
3. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure (COMPANION). N Engl J Med 2004;350:2140-50.
4. Bunch TJ, Hohnloser SH, Gersh BJ. Mechanisms of sudden cardiac death in myocardial infarction survivors: Insights from the randomized trials of implantable cardioverter-defibrillators. Circulation 2007;115:2451-7.
5. Bigger JT Jr, Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337:1569-1575.
6. Veenhuyzen GD, Singh SN, McAreavey D, Shelton BJ, Exner DV. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation 2001;104:1489-1493.
7. Bigger JT Jr, Whang W, Rottman JN, Kleiger RE, Gottlieb CD, Namerow PB et al. Mechanisms of death in the CABG Patch trial: A randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999;99:1416-1421.
8. Risum O, Nitter-Hauge S, Abdelnoor M, Levorstad K, Arafa O, Svennevig JL. Mortality and morbidity after coronary artery bypass surgery related to pre-operative left ventricular ejection fraction: A follow-up study. Eur Heart J 1996;17:874-9.
9. Budeus M, Feindt P, Gams E, Wieneke H, Erbel R, Sack S. Risk factors of ventricular tachyarrhythmias after coronary artery bypass grafting. Int J Cardiol 2006; 113:201-8.
10. Huikuri HV, Yli-Mäyry S, Korhonen UR, Airaksinen KE, Ikäheimo MJ, Linnaluoto MK et al. Prevalence and prognostic significance of complex ventricular arrhythmias after coronary arterial bypass graft surgery. Int J Cardiol 1990;27: 333-9.
11. Mäkikallio TH, Barthel P, Schneider R, Bauer A, Tapanainen JM, Tulppo MP et al. Prediction of sudden cardiac death after acute myocardial infarction: Role of Holter monitoring in the modern treatment era. Eur Heart J 2005;26:762-9.
12. Brembilla-Perrot B, Villemot JP, Carteaux JP, Haouzi A, Amrein D, Schöth B et al. Postoperative ventricular arrhythmias after cardiac surgery: Immediate- and longterm significance. Pacing Clin Electrophysiol 2003;26:619-25.
13. Bell MR, Gersh BJ, Schaff HV, Holmes DR Jr, Fisher LD, Alderman EL et al. Effect of completeness of revascularization on long-term outcome of patients with three-vessel disease undergoing coronary artery bypass surgery. A report from the Coronary Artery Surgery Study (CASS) Registry. Circulation 1992;86:446-57.
14. Jones EL, Weintraub WS. The importance of completeness of revascularization during long-term follow-up after coronary artery operations. J Thorac Cardiovasc Surg 1996;112:227-37.
15. Kleisli T, Cheng W, Jacobs MJ, Mirocha J, Derobertis MA, Kass RM et al. In the current era, complete revascularization improves survival after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2005;129:1283-91.
16. Sanders GD, Al-Khatib SM, Berliner E, Bigger JT, Buxton AE, Califf RM et al. Expert panel participating in a Duke Center for the Prevention of Sudden Cardiac Death-sponsored conference. Preventing tomorrow's sudden cardiac death today: Part II: Translating sudden cardiac death risk assessment strategies into practice and policy. Am Heart J 2007;153:951-9.
17. Buxton AE. Identifying the high risk patient with coronary artery disease-is ejection fraction all you neeď J Cardiovasc Electrophysiol 2005;1(16 Suppl): S25-7.
18. Myerburg RJ. Sudden cardiac death: Exploring the limits of our knowledge. J Cardiovasc Electrophysiol 2001;12:369-81.
19. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS et al. American College of Cardiology/American Heart Association Task Force on Practice; American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities executive summary. Heart Rhythm 2008;5:934-55.
20. Mäkikallio TH, Barthel P, Schneider R, Bauer A, Tapanainen JM, Tulppo MP et al. Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. Am J Cardiol 2006;97: 480-4.
21. Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML et al. MADIT-II Investigators. Time Dependence of Defibrillator Benefit After Coronary Revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:1811-7.
22. Al-Khatib SM, Hellkamp AS, Lee KL, Anderson J, Poole JE, Mark DB et al. Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). scd-heft investigators. J Cardiovasc Electrophysiol 2008;19:1059-65.
23. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR et al. MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: Lessons from the MUSTT study. J Am Coll Cardiol 2007;50:1150-7.
24. Paolucci M, Cattafi G, Magenta G, Vecchi MR, Schirru M, Lunati M. Risk stratification for sudden cardiac death: Should we just consider ejection fractioň. G Ital Cardiol (Rome) 2008;10:27S-32S.
25. Huikuri HV, Mäkikallio TH, Raatikainen MJ, Perkiömäki J, Castellanos A, Myerburg RJ. Prediction of sudden cardiac death: Appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation 2003;108: 110-5.
26. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006;114:2766-72.
27. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.